Arecor Therapeutics PLC's (AIM:AREC) CEO Sarah Howell talked with Proactive's Stephen Gunnion about the company’s second-half performance and its strategic priorities heading into 2026, highlighting progress across its dual focus on diabetes and oral peptide delivery.

Howell explained that Arecor is a clinical-stage biopharmaceutical company focused on drug development and enhanced delivery in the cardiometabolic space. The company’s lead asset, AT278, is described as a “new unique best-in-class ultra-concentrated (500 U/mL) and ultra-rapid-acting insulin for the treatment of diabetes,” and is now progressing through a 50:50 co-development partnership with Sequel Med Tech. The collaboration is preparing for a pivotal phase two clinical study, which Arecor is targeting to begin in the second half of 2026.

She noted that both teams share a vision of combining next-generation automated insulin delivery (AID) systems with next-generation insulin to improve patient outcomes and reduce disease management burden. Positive negotiations are also underway regarding a broader co-development and commercialisation partnership.

On the oral GLP-1 programme, Howell highlighted the challenge of bioavailability, pointing out that Rybelsus (semaglutide), an oral GLP-1 tablet for adults with type 2 diabetes, currently achieves “less than 1% oral bioavailability.” Arecor is conducting nonclinical pharmacokinetic studies aimed at improving bioavailability, which could be highly translatable across multiple peptide therapeutics.

Financially, the company reported unaudited revenues of £3.1 million for 2025 and cash of £6.1 million at year-end, extending the runway into the first half of 2027.

For more insights into Arecor Therapeutics PLC’s strategy and upcoming milestones, visit Proactive’s YouTube channel, like this video, subscribe to the channel and enable notifications so you never miss future updates.

#ArecorTherapeutics #SarahHowell #AT278 #DiabetesTreatment #InsulinInnovation #OralGLP1 #GLP1 #PeptideTherapeutics #BiotechNews #ClinicalTrials #Phase2Trial #MedTech #Cardiometabolic #HealthcareInnovation #ProactiveInvestors

Genflow Biosciences Ltd (LSE:GENF, OTCQB:GENFF, FRA:WQ5) CEO Dr Eric Leire talked with Proactive's Stephen Gunnion about the company’s latest RNS regarding its upcoming AGM and the strategic rationale behind authorising the potential issuance of shares ahead of clinical partnership discussions.

Leire addressed potential shareholder concerns, acknowledging that announcements involving share issuance can sometimes be interpreted as a fundraising signal. However, he clarified that the RNS is not about launching a capital raise, but about strengthening the company’s position in ongoing and future negotiations with major pharmaceutical partners.

He explained that in biotech, financial flexibility translates directly into leverage. “In biotech, cash is not just money, it's negotiating power,” Leire said. As a public company, Genflow's financial position is visible to potential partners, and Leire emphasised the importance of maintaining the ability to walk away from unfavourable terms.

He added that the company is not committing to using the full 38% share issuance authority and stressed that the underlying science remains unchanged. “Our science has not changed. What we're doing is just making sure that we capture the full value of our science,” he noted.

While acknowledging that markets dislike uncertainty, Leire stated that uncertainty is temporary, whereas signing a bad deal would have lasting consequences. He said the company is focused on optimising for the best long-term outcome and ensuring it is not forced into a suboptimal agreement.

For more updates like this, visit Proactive’s YouTube channel, give this video a like, subscribe to the channel and enable notifications so you don’t miss future content.

#GenflowBiosciences #BiotechNews #BiotechInvesting #PharmaPartnership #LifeSciences #AGMUpdate

#HealthcareStocks #ClinicalPartnerships #SmallCapStocks #UKBiotech

S&U PLC (LSE:SUS) chairman Anthony Coombs talked with Proactive's Stephen Gunnion about the company’s continued growth momentum, particularly across its Advantage and Aspen divisions. Following a challenging regulatory period, Coombs reported a significant rebound in confidence, performance, and strategic clarity.

The company is forecasting its receivables to grow from c. £400 million to £600 million in the coming years. “There’s significant growth available in the Advantage business, but also in Aspen too; but particularly the Advantage business,” Coombs explained. He attributed this optimism to tightened credit scoring, improved affordability criteria, and an ongoing AI project aimed at operational efficiency.

Despite a sluggish property market impacting Aspen, the division exceeded budget with record sales and collections. Coombs acknowledged market headwinds—ranging from political uncertainty to interest rate volatility—but emphasised the resilience of S&U’s approach and the discipline underpinning its lending practices.

Investors have taken notice, with the share price up 20%, reflecting renewed interest in smaller-cap financials and confidence in S&U’s forward trajectory. Coombs noted, “They recognise the business has come out of a difficult period and is now regaining its va va voom.”

Looking ahead to 2026, Coombs acknowledged economic uncertainties but maintained a positive outlook, provided conditions remain reasonably stable. He reiterated the company’s focus on responsible lending, honed over its 88-year history.

Visit Proactive’s YouTube channel for more videos, and don’t forget to give the video a like, subscribe to the channel and enable notifications for future content.

#SUPLC #AnthonyCoombs #UKFinancials #AutoFinance #AdvantageFinance #AspenBridging #UKEconomy #ReceivablesGrowth #SmallCapStocks #ResponsibleLending #FinancialServices #InvestingInUK #AIInFinance #RegulatoryRecovery #ProactiveInvestors

KEFI Gold and Copper PLC (AIM:KEFI, OTC:KFFLF, FRA:KMSA) executive chairman Harry Anagnostaras-Adams talked with Proactive's Stephen Gunnion about closing the company’s full US$340 million project financing following a US$20 million investment from Chancery Royalty, marking what he described as a confirmatory milestone rather than a fundamental change in strategy.

Speaking from the Mining Indaba in Cape Town, Anagnostaras-Adams explained that bank approvals secured in October covered 70% of development capital, allowing KEFI to optimise the remaining equity components. He highlighted that the company structured the financing largely at the subsidiary level, reducing dilution at the parent company. The latest US$20 million funding was arranged as an “equity ranking royalty,” designed so that payments are only made when dividends are payable to shareholders.

“A conventional royalty gets paid before operating expenses… this has been deliberately positioned so that it only gets paid when dividends can get paid,” he said, emphasising alignment with shareholder interests.

The project, valued at approximately US$400 million, has been financed in a way that minimised equity dilution, including contractor arrangements that reduced capital requirements to US$340 million and the participation of a major development bank for US$240 million.

Discussing valuation, Anagnostaras-Adams noted the stock has tripled over the past six months and said benchmarking against similar-stage gold companies suggests further potential upside, although he stressed that market movements are outside management’s control.

At Indaba, KEFI has been meeting contractors, capital providers, insurers and government representatives as mobilisation begins. “We’ve pressed the button, we’re launching fully,” he said, describing activity across site locations and contractor hubs globally.

For more interviews like this, visit Proactive’s YouTube channel, give this video a like, subscribe to the channel and enable notifications so you don’t miss future updates.

#KEFIGold #GoldMining #ProjectFinance #MiningInvestment #GoldStocks #MiningIndaba #ResourceInvesting #RoyaltyFinance #CopperExploration #StockMarketNews

Immunic Inc (NASDAQ:IMUX) chief medical officer Dr Andreas Muehler talked with Proactive's Stephen Gunnion about the latest data presented at the ACTRIMS Forum in San Diego, highlighting findings from the company’s Phase 2 CALLIPER trial in progressive multiple sclerosis (MS).

The discussion centered on two posters shared at the conference: one focusing on MRI outcomes and the other exploring EBV (Epstein-Barr Virus) reactivation. Muehler explained that vidofludimus calcium demonstrated reductions in gadolinium-enhancing and T2 lesions as well as slowly expanding lesions (SELs) - indicators of acute and chronic inflammation in MS, respectively.

He outlined how MRI scans detected fewer SELs in treated patients, providing early clinical signs that vidofludimus calcium could address both peripheral and central nervous system inflammation in progressive MS.

“These data from the CALLIPER trial really show for the first time that there's also clinical evidence that vidofludimus calcium is causing a statistically significant reduction in EBV reactivation with treatment over time as compared to placebo,” said Muehler.

The EBV-related findings were particularly important, as mounting evidence suggests the virus is a necessary condition for MS. The company measured T-cell receptor repertoires and found a clear drop in EBV antigens among patients treated with vidofludimus calcium, suggesting reduced reactivation activity.

Looking ahead, Muehler pointed to 2026 as a potential pivotal year, with the company expecting readouts from its two phase 3 trials in relapsing MS involving over 2,000 patients. These results are expected to inform regulatory submissions and could bring Immunic’s treatment closer to market.

Visit Proactive's YouTube channel for more interviews, and don't forget to give this video a like, subscribe to our channel, and enable notifications so you never miss an update.

#ImmunicInc #MSResearch #ProgressiveMS #VidofludimusCalcium #EBV #MultipleSclerosis #BiotechNews #ClinicalTrials #MSAwareness #MRIResearch #Neuroscience #PharmaInnovation #SELlesions #Phase2Trial #MSInflammation

Novo Resources Corp Executive Co-Chairman Mike Spreadborough and Kas De Luca, the company's Exploration General Manager Kas De Luca joined Steve Darling from Proactive to discuss the company’s latest exploration target update at its Belltopper gold project in Victoria, highlighting a significant upgrade to the project’s potential and outlining plans for renewed drilling in 2026.

The Belltopper project is located approximately 60 kilometres south of Agnico Eagle’s Fosterville gold mine and lies within the highly prospective Bendigo Tectonic Zone, one of Victoria’s most prolific gold-producing regions. De Luca explained that Novo has undertaken an extensive integration of historical datasets, including legacy underground workings, into a comprehensive and detailed 3D geological model to better inform its exploration strategy.

“We’ve captured it all in a really good 3D model, so it really speaks to both the geology and the mineralisation,” De Luca said, noting that the model has significantly improved the company’s understanding of the controls on gold mineralisation at Belltopper.

As a result of this work, Novo has now defined eight prospective quartz reef systems across the project area, with several reefs extending up to two kilometres along strike at surface. The updated 2026 exploration target outlines a high-case scenario of up to 880,000 ounces of gold at an average grade of 8.9 grams per tonne, representing a 48% increase compared with the previous exploration model.

Spreadborough said the upgraded exploration target and improved geological confidence have positioned the company to advance the project toward the next phase. Novo is now seeking the necessary approvals and is planning to recommence drilling in the third quarter of 2026.

“We’re planning to go back drilling starting in July and continue through the rest of the year,” Spreadborough said, adding that the upcoming program is designed to test the most prospective reefs identified by the updated model and further unlock the project’s discovery potential.

#proactiveinvestors #novoresources #asx #nvo #tsx #nvo #otcqb #nsrpf #NovoResources #BelltopperProject #VictoriaGold #GoldExploration #BendigoTectonicZone #QuartzReef #3DGeology #MiningExploration #Drilling2026 #GoldMineralisation #HighGradeGold #ResourceUpgrade #PreciousMetals #AustralianMining #FutureMines

Ecora Royalties PLC (LSE:ECOR, TSX:ECOR, OTCQX:ECRAF, FRA:HGR) CEO Marc Bishop Lafleche talked with Proactive's Stephen Gunnion about a pivotal period for the company as it enters a new phase of growth driven by base metals and critical minerals.

Lafleche explained that 2025 marked an inflection point for Ecora Royalties, with base metals and critical minerals representing the majority of portfolio revenue for the first time in at least 25 years. He described the year as a “landmark year,” highlighting that the performance was underpinned by a 150% increase in base metals revenue compared with 2024.

The CEO outlined how this momentum was driven by a combination of higher production volumes and favourable commodity prices. Strong volume growth was recorded at the Voisey’s Bay cobalt stream, as the mine continued to ramp up, with further increases expected. Additional growth came from the Mimbula copper stream, acquired in March last year, which is now operating at an annualised rate of around 20,000 tonnes of copper and is expected to expand further through 2026. Mantos Blancos also delivered a standout performance following debottlenecking initiatives completed in 2024.

Discussing the balance sheet, Bishop Lafleche noted that despite acquiring a US$50 million producing copper stream, net debt had reduced from nearly US$130 million to approximately US$85 million by the end of Q4, supported by strong cash flow generation. He said, “that really strong deleveraging is in part a function of the strong cash flow generation of this portfolio.”

Looking ahead, the CEO highlighted layered growth opportunities, including production increases at existing assets, brownfield expansions, near-term development projects such as Santo Domingo and West Musgrave, and longer-term catalysts across the portfolio. With supportive commodity prices for copper, cobalt and uranium, he said the outlook for Ecora Royalties remains very positive.

For more interviews and insights like this, visit **Proactive’s YouTube channel**, and don’t forget to **like the video, subscribe to the channel, and enable notifications** so you never miss an update.

#EcoraRoyalties #MarcBishopLafleche #MiningRoyalties #BaseMetals #Copper #Cobalt #CriticalMinerals #MiningStocks #ResourceInvesting #Commodities #MiningCEO #ProactiveInvestors

Leading Edge Materials CEO Kurt Budge joined Steve Darling from Proactive to share news that the company’s wholly owned Swedish subsidiary, Greenna Mineral AB (GMAB), has signed a memorandum of understanding (MoU) with Ascension Earth Resources. The agreement marks an important step in evaluating innovative processing approaches for the Norra Kärr rare earth element (REE) project in Sweden.

Budge told Proactive that, under the terms of the MoU, GMAB will supply eudialyte mineral samples from the Norra Kärr deposit to Ascension. Ascension will carry out comprehensive laboratory analysis and metallurgical testwork using its proprietary processing technology. The collaboration is designed to assess both the technical and commercial feasibility of extracting and recovering rare earth elements—particularly heavy rare earth elements (HREEs)—from the HREE-bearing eudialyte mineralisation at Norra Kärr.

The Evaluation Project will focus on several key workstreams, including detailed mineralogical and chemical analysis of the eudialyte samples to determine their composition, purity, and recovery potential. Testwork will also examine leaching behaviour and assess the suitability of the mineralisation for commercial-scale processing. In parallel, Ascension will work on developing preliminary processing concepts specifically tailored to the unique characteristics of the Norra Kärr deposit, alongside an evaluation of the overall commercial viability of rare earth extraction.

Budge also shared with Proactive a significant near-term catalyst is the pending decision from Sweden’s mining inspectorate on a 25-year mining lease for Norra Kärr, following endorsements from two regional governments in December 2025. Budge described this lease as a potential "game changer" in terms of de-risking the project.

Additionally, Leading Edge is making progress on its Romanian Bihor Sud project, where a Competent Person’s Report has been completed, potentially paving the way for new investment.

#proactiveinvestors #leadignedgematerials #tsxv #lem #nasdaq #lemse #otcqb #lemif #NorraKarr #RareEarths #REE #HeavyRareEarths #HREE #CriticalMinerals #GreennaMineral #AscensionEarthResources #SwedenMining #Eudialyte #Metallurgy #MiningInnovation #StrategicPartnership #EnergyTransition #CleanTech #EuropeanResources #BatteryMaterials #SustainableMining

Nextech3D.ai CEO Evan Gappelberg joined Steve Darling from Proactive to announce the expansion of the company’s enterprise platform into corporate gifting, creating a new high-margin growth vertical for 2026 and beyond.

Gappelberg told Proactive that the global corporate gifting market is a massive and rapidly growing industry, currently valued at approximately $920 billion in 2025. Driven by strategic shifts toward year-round employee engagement, client retention, and personalized incentives, the market is projected to exceed $1.65 trillion by 2033, maintaining a steady annual growth rate of roughly 8%.

The corporate gifting and rewards market is increasingly driven by enterprise demand for employee recognition, customer loyalty programs, incentive campaigns, and experiential gifting. Nextech3D.ai believes it is uniquely positioned to capture a meaningful share of this expanding market, thanks to its AI-powered platform that integrates data-driven insights, personalization, and scalable deployment.

Nextech3D.ai’s corporate gifting solution is fully integrated into its existing enterprise ecosystem, allowing multinational customers to deploy AI-driven, data-backed gifting and experiential campaigns alongside events, team-building exercises, and broader engagement initiatives. By consolidating multiple enterprise engagement functions into one unified platform, Nextech3D.ai aims to enhance operational efficiency while delivering impactful and measurable engagement outcomes.

Gappelberg noted that the move into corporate gifting complements the company’s ongoing expansion of Krafty Lab and other enterprise services, creating a cohesive, end-to-end solution for organizations seeking scalable and innovative engagement strategies.

#nextech3d.al #otcqx #nexcf #cse #ntar #EvanGappelberg #CorporateGifting #EnterpriseSolutions #EmployeeEngagement #ClientRetention #AIPlatform #IncentivePrograms #CorporateRewards #ExperientialGifting #HRTech #TeamBuilding #BusinessGrowth #TechInnovation #2026Growth #DataDrivenInsights

Pluri Inc CEO Yaky Yanay joined Steve Darling from Proactive to provide deeper insight into the company’s proprietary cell expansion technology and its strategic growth across both therapeutics and food technology. Yanay noted that Pluri has invested more than two decades in developing what he described as one of the most advanced and effective cell expansion systems globally, supported by an intellectual property portfolio of approximately 250 patents.

Pluri currently operates across two core verticals. The first is focused on longevity, therapeutics, and aesthetics, where the company leverages placenta-derived cells to develop innovative biological solutions. The second vertical is centered on food technology, where Pluri’s scalable platform enables the production of cultivated meat, as well as key ingredients such as coffee, cocoa, and other agricultural inputs designed to address sustainability and supply chain challenges.

Yanay also told Proactive that the company has successfully completed the first phase of its collaboration with Resbiomed Technologies OOD, a European biotechnology company specializing in extracellular-matrix (ECM)–based biomaterials and biologics for regenerative medicine. The program is being executed through Pluri’s contract development and manufacturing organization, PluriCDMO™.

He explained that the initial phase of the collaboration focused on early-stage process development and feasibility assessments, all of which have now been completed. With these objectives achieved, the program is advancing into its next phase, representing a meaningful milestone in the partnership and setting the foundation for further development work.

As part of the collaboration, Pluri is applying its proprietary placenta-based technologies and advanced bioprocessing expertise to assist Resbiomed in establishing robust protocols for tissue extraction, separation, and processing. These processes are designed to preserve, concentrate, and enhance endogenous collagen components, enabling the production of high-quality biological materials suitable for a broad range of regenerative medicine applications. The work builds on Pluri’s proven experience in placenta-derived manufacturing while complementing Resbiomed’s specialized focus on ECM-based biomaterials.

Human collagen and collagen-rich materials are considered premium biological inputs due to strict sourcing, regulatory, and quality requirements. By combining Pluri’s scalable manufacturing capabilities with Resbiomed’s biomaterials expertise, the collaboration aims to help address these challenges and support the development of next-generation regenerative therapies.

From Pluri’s perspective, the agreement highlights the growing demand for PluriCDMO™ services among companies developing advanced cell- and tissue-based technologies. Yanay emphasized that the collaboration further strengthens PluriCDMO’s position as a trusted partner for biologics and advanced biomaterials programs that require reproducibility, scalability, and rigorous manufacturing controls as they progress toward clinical and commercial development.

#proactiveinvetors #nasdaq #tase #plur #yakyyanay #biotech #PluriCDMO #Resbiomed #RegenerativeMedicine #Biotechnology #ECMBiomaterials #Collagen #BiologicsManufacturing #CDMO #AdvancedTherapies #PlacentaBasedTech #TissueEngineering #LifeSciences #Bioprocessing #ProactiveInvestors